Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. 1994

A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486.

Human monoclonal antibody 447-52D binds to the V3 determinant of the human immunodeficiency virus type 1 (HIV-1) gp120 external glycoprotein. Its binding requires the expression of the GPxR sequence at the center of the V3 domain. HIV-1 variants that are adapted to replication in T-lymphoid cell lines and express this sequence motif are efficiently neutralized by the antibody (M. K. Gorny, A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner, J. Virol. 66:7538-7542, 1992). In the present study, the antiviral activity of 447-52D was further defined with regard to its ability to mediate neutralization of primary HIV-1 clinical isolates. Again, the antibody was found to potently neutralize those isolates that expressed the binding sequence. We confirmed that this determinant is commonly expressed by virus isolates belonging to the subtype (clade) B sequence classification. As such, 447-52D may be useful for prophylactic and immunotherapeutic intervention. In addition, the study demonstrated that neutralization of primary HIV-1 isolates is possible if mediated by an appropriate antibody.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
February 2004, Structure (London, England : 1993),
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
December 1998, Journal of virology,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
December 2001, Journal of virology,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
April 1994, Proceedings of the National Academy of Sciences of the United States of America,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
January 2002, Microbiology and immunology,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
December 1991, Proceedings of the National Academy of Sciences of the United States of America,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
November 2015, Scientific reports,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
July 1992, The Journal of infectious diseases,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
May 1997, AIDS research and human retroviruses,
A J Conley, and M K Gorny, and J A Kessler, and L J Boots, and M Ossorio-Castro, and S Koenig, and D W Lineberger, and E A Emini, and C Williams, and S Zolla-Pazner
June 1998, The Journal of infectious diseases,
Copied contents to your clipboard!